HOME >> MEDICINE >> NEWS
OHSU scientists test medication to treat involuntary weight loss

PORTLAND, Ore. Scientists at Oregon Health & Science University, in collaboration with Neurocrine Biosciences Inc., have successfully tested a research medication that both stimulates appetite and reduces metabolic rate in preclinical trials. Neurocrine, which developed the test medication for this research, is now developing a related medication that will likely be tested in patients suffering from a common, disease-related form of malnutrition and involuntary weight loss called cachexia. The results of the research are published in the current online edition of the journal Endocrinology.

"We've all seen AIDS and cancer patients who lose their appetites and suffer from involuntary weight loss. They lose muscle mass and become very frail as their disease progresses -- this is what we refer to as cachexia," explains Daniel Marks, M.D., Ph.D., a member of the OHSU Center for Weight Regulation and Associated Disorders and an assistant professor of pediatric endocrinology in the OHSU School of Medicine. "Cachexia is a very serious and currently untreatable disorder that can often impede the battle against the related disease. For instance, cancer patients who are malnourished due to cachexia cannot undergo intense chemotherapy simply because their bodies are too frail to handle it. If we can prevent cachexia and keep these patients from deteriorating physically, it gives them a greater chance of surviving the disease they are fighting."

This latest research breakthrough is based on earlier studies that demonstrated how a receptor on certain brain cells -- called the MC4 receptor -- can influence metabolism and appetite. Previous research involving mice demonstrated that when this specific cell receptor is blocked by delivering medications directly to the brain, the effects of cachexia are reversed. The animals' appetite and weight increase while their metabolic rate decreases. The next step in the research process, and the goal of this study, wa
'"/>

Contact: Jim Newman
newmanj@ohsu.edu
503 494-8231
Oregon Health & Science University
29-Mar-2005


Page: 1 2 3

Related medicine news :

1. Earlier use of prostate cancer vaccines urged by Hopkins scientists
2. Tobacco industry pays scientists to challenge secondhand smokes link to infant death risk
3. Schepens scientists regenerate optic nerve for the first time
4. OHSU scientists develop MRI approach to improve breast cancer detection
5. UCLA neuroscientists pinpoint new function for mirror neurons
6. Jefferson scientists uncover potential trigger of diabetic kidney disease
7. Johns Hopkins scientists receive presidential medals
8. UCLA brain scientists crack mystery of how alcohol causes intoxication
9. Wisconsin scientists grow critical nerve cells
10. Jefferson scientists help explain statins effects in Alzheimers disease
11. Jefferson scientists find zinc may help prevent esophageal, oral cancers

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of ... Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, ... In honor of Morris F. Collen, a pioneer in the field of medical informatics, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards ... recognizes editorial and design excellence across a range of sectors. This year’s program included ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, ... relay – Miles by Moonlight to raise money for the American Heart Association Heart ... , Teams will work together to keep their treadmills moving for 5 hours. ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... 2017 West Pharmaceutical Services, Inc. ... injectable drug administration, today announced that it will release ... Thursday, October 26, 2017, and will follow with a ... at 9:00 a.m. Eastern Time. To participate on the ... conference ID is 94093362. ...
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/4/2017)... -- According to the Centers for Disease Control and Prevention (CDC), influenza ... Care is helping communities across Massachusetts , ... no-cost* flu shots through the end of the month. *Some ... ... flu shot is by the end of October, according to the Centers ...
Breaking Medicine Technology:
Cached News: